Coronavirus Disease 2019 (COVID-19) Surveillance Worksheet

NAME					ADDRESS (Street and No.)						PHONE Hospital Record No.					
(las	t)			(first)	This	s information	will not be	e sent t	to CDC							
REPORTIN	ie som	RCF T	VPF	NAME			LC	DCAL	ID							
□ physicia				ADDRESS				IBIEC								
□ nurse		bora		ZIP CODE					ESS STATE							
			•			JBJEC	T ADDRE	ss cou	JNTY _							
□ other so					SUBJECT ADDR						PRESS ZIP CODE					
						CASE IN	ORMA	TION								
NNDSS ID			_	Date of B	irth		Birth		Othe	er Birthplace						
(Local Reco			:-/!-+:	no NI Not I	month da	•										
Ethilic Gro	I				lispanic/Latino	0 =0ther			U =Unknov		Country of Usual Residence					
RACE	America	an India	an/Ala	skan Native	Asian				White		Refused to answer Unknown					
	Black/A	frican <i>i</i>	Americ	an	Native Ha	awaiian/Pacifi	Sislander		Not asked		Other					
Sex M=ma	ile F =fen	nale L	J =unkn	iown	Age at Cas	e Investiga	tion		Age Uni	t*	Date	Reported				
Reporting	State _		Earl	iest Date R	eported to	State			Date Fire	st Repo	rted to	PHD	 n day year			
Reporting	County	/		Earliest D	ate Reporte					National Reporting Jurisdiction						
					I I						probable case, reason for case					
CDC 2019	-nCOV I	D _			Positive S	`````		assification:								
Coop Inves	-4:4:-	_			1 OSICIVE S	YYYY)		Meets clinical criteria AND epidemiologic evidence with								
Case Inve	_		day		CASE □ Confirmed no confirmatory lab testing performed for COVI							-				
Start Date		month	uay	yeai	CLASS □ Probable □ Unknown O Meets presumptive lab evidence AND either clinical								ND either clinical			
DGMQID					criteria OR epidemiologic evidence											
[If Epi-X notifi	ication of t	ravelers	checke	ed, DGMQID]	SIAIUS						Meets vital records criteria with no confirmatory lab					
		Auto	opsy				Laborat	ory re	ported		Other method (specify below)					
DETECTION	ON	Clini	ical ev	aluation			Provide	r repo	orted							
METHO	D	Con	tact tr	acing of cas	e patient		Routine	physi	ical examir	nation	Ur	nknown				
		Epi-	X noti	fication of tr	avelers		Routine	surve	eillance		Previ	ous State C	ase ID			
Did case p	oatient _l	previo	ously	meet the c	ase definiti	on for prob	able or o	confir	med case	of SAF	RS-CoV-2	2? Y=yes N	l=no U =unknown			
					HOS	PITALIZATI	ON INF	ORM	ATION							
Illness On	set Date	e	n day	year	Illness End	Date		 year	Illness	Durat	ion	Durat	ion Units*			
Hospitaliz	ed? Y=y	es N =r	no U =u	ınknown 🗌	Hospital A	dmission D				Hosp	ital Disc	harge Dat	e			
Duration	of Hosp	ital S	•	0 – 998	Pat	ient admitt	ed to an	Inte	nsive Card	e Unit (ICU)? Y	′ =yes N =no	U =unknown			
If hospital	lized, w	as a t	ransla	ator/Interp	reter requi	red? Y=yes	N=no U	J =unkn	own	ICU A	dmissio	n Date	nth day year			
If a transla	ator wa	s req	uired,	, specify th	e patient's p	orimary lang	guage:			ICU E	Discharg	e Date	nth day year			
Pregnant	at time	of ev	ent?	Y=yes N=no	U =unknown	If yes,	trimest	er at	illness on	set:	Nun	nber Week	s Gestation			
Did subje	Did subject die from illness/complications of illness? Y=yes N=no U=unknown Date of Death															
	•	*UNITS	a=y	vear d=da	y h=hour	min=minute	mo=mo	nth	s=second	wk=w	veek l	JNK=unknow	/n			

						CLI	NIC	AL II	NFORMATI	ON												
INFORMATION	sou	JRCE		Medical records				tient ir	nterview] Ui	nkno	wn			DAT	E of						
for CLINICAL	DAT	Ά		Ot	her (specify)									D	IAG	NOSIS	month	day	year			
	-	Asym	ptor	natic te	esting			Scre	ening						U	nknown						
TESTING			<u> </u>	nvestiga		_			er (specify)													
REASON				ity testi		-		Symptomatic FIRST POSITIVE														
CARC CoV 2 line	_		0 , ,	P • • • • • • • • • • • • • • • • • • •				\dashv			IMEN											
SARS-CoV-2 lineage designation or sublineage: If available. WHO Greek alphabet nomenclature is preferred for vi									variants of concorn (ov. Omicron BA 1)							ΙTE	month	day	year			
Symptoms prese													om(s	s) re	solv	e? Y =yes	N =no	U =unk	nown			
Did the patient have another diagnosis/etiology for illness? Y=yes N=no U=unknown (if yes, specify)																						
	Υ	N	U	[Y=yes	:1	Υ	N	U	[N=no]				Гу	N	U	[U=unkno	wnl					
				Abdominal pain					Subjective fev	ver						Rigors						
				Chest					Fever >100.4	F (38	C)					Runny nose						
				Chills					Headache							Sore thro	at					
SIGNS and				Cough					Inability to st	ay av	vake					Vomiting						
SYMPTOMS				Cyano	Cyanosis				Nausea							Wheezing						
				Diarrh					New confusio							Other (specify)						
					llty breathing				New olfactory disorder													
				Drows	•				New taste disorder							Persistent pressure in chest						
				Dyspn Fatigu					Muscle aches	Muscle aches						Unknown	<u> </u>	e in che	251			
				1 atiga					Widdele defied							Onknown						
	Y	N	U	NA	[Y=yes; N=no; U	=unk	now	n]		Υ	N	U	N/			not applical	ole]					
CLINICAL					Acute respiratory	y dist	ress	syndro	ome (ARDS)					(Other	(specify) _				_		
FINDINGS					Abnormal electro	ocard	liogr	am (Ek	(G)					ı	Pneur	nonia						
					Abnormal chest						Unknown											
	Υ	N	U	[Y=ve	s; N=no; U=unk	now	n]	D	URATION (day	s)	Υ	N	U				DU	RATION	V (days	s)		
TREATMENT					anical ventilation/			n						Oth	er (sp	ecify)						
TYPE				ECMO	<u> </u>										nown							
Did the case pat	ient	have	e un	derlyi	ng medical con	diti	ons	and/	or risk heha	vio	rs?	v	=yes		l=no	U =unkn	own [
Underlying Cond									se for each							=unknown)						
CONDITION/DI				Y/N/U	CONDITION/DIS			Y/N/U	CONDI					- 1	//N/U	1	TION/DIS	ORDER		Y/N/U		
Attention Deficit Hyper	activi	ity Dis	order		Chronic renal dise				Hypertension		<u> </u>			_		Pulmonary	-					
Autoimmune condition		-			Congenital heart	diseas	se		Idiopathic pul	mona	ary fil	orosis				Pulmonary	hyperten	ision				
Birth defects disorder					COPD				Immunosupp	ressiv	e cor	ndition	า			Secondary	immune (deficien	су			
Blood stem cell transpl	ant				Coronary heart di	sease			Intellectual/d	evelo	pmei	ntal di	isabilit	у		Severe obe	sity (BMI	≥40)				
Bronchiectasis					Current smoker				Interstitial lur	ng dis	ease					Spinal cord	injury					
Bronchopulmonary dys	plasia	a			Cystic fibrosis				Former smoke	er						Stroke						
Cancer					Dementia				Learning disal	oility						Substance	abuse/mi	suse				
Cardiomyopathy					Depression				Longterm cor	ticost	teroic	luse				Tuberculos	is					
Cardiovascular disease					Diabetes mellitus				Obesity							Unknown						
Cerebral palsy					Disability†				Organ transpl	ant						Other chronic disease (specify)						
Cerebrovascular diseas	e				Down syndrome				Overweight							Other chronic disease (specify)						
Chemotherapy					Emphysema				Pregnancy							Other unde	erlying (sp	ecify)				
Chronic bronchitis					Heart failure				Primary immu	ıne d	eficie	ncy						.,				
Chronic liver disease					HIV infection				Psychological,			•										
Chronic lung disease					†If disability, type	2							ment	al co	nditio	າ, type						
														501		, -,,,,						

						D	EMO	OGRA	PHIC IN	IFO	RMATION	I								
Tribal affili	ation	Y =ye	es N =n	o U =unkn	own [Trib	al Na	me 🗌] En	rolled	Tril	be N	lame				
DECIDENCE		Acut	e care in	patient facili	ty	Н	omel	ess she	lter		Long teri	m care	facility	,		Othe	er (spe	ecify) _		
RESIDENCE at ILLNESS		Apar	tment			Н	otel				Mobile h	ome				Outs	ide			
ONSET		Assis	sted living	g facility		Н	ouse/	'single	family		Motel					Reha	bilita	tion fac	cility	
C.1.6_1.		Corre	ectional f	facility		G	roup	home			Nursing l	nome				Unkı	nown			
Was case-p	atien	t a he	ealthca	re person	nel (HC	CP) a	t tim	ne of i	illness o	onse	et? Y=yes	N =no	U =unl	knov	wn [I:	f yes,	, selec	t from below	/ :
НСР			Environr	mental servi	es		Nurs	e			CD		Assiste	ed li	ving	facility	/	F	Iospital	
OCCUPAT	ON		Respirat	ory therapis	:		Phys	ician			CP A CE		Long-t	term	n care	e facili	ty	N	lursing home	
TYPE			Other				Unkr			(PLACE		Rehab	ilita	tion	facility	/	Unknown			
										SEI	TING		Other	(spe	ecify)					_
	EXPOSURE and IMPORTATION INFORMATION																			
In the 14 d	In the 14 days prior to illness onset, did the patient have any of the following exposures: (check all that apply)																			
Y N U			, U=unkno	wn]		Υ	N	U						Υ	N	U				
	Airpo	•		6 1111					Other (sp										l travel	
	Childo			ng facility					Correction								Schoo	ol/univ	ersity	
				ass gatherin	σ				Domestic travel Unknown exposures in the 14 days prior to illness onset											
				spected COVII		An	Animal Type													
	Work	•			- ,				Workpla	ce cr	itical infrast	tructu	re?	Sett	ting (specif	y)		-	
		or vessel	Na	me o							2) _		•							
Contact with confirmed/probable COVID-19 case: O community O healthcare associated O household O other O unknown											O unknowi	n								
	If contact with COVID-19 case, was this person a US case? Linked Case Number																			
	Inte	rnati	ional		Coun	ry			Departure Date (mm/dd/yyyy)							ŀ	eturn	ı Date (mm/dd/yyyy)	
		tinat																		
									_						-					
TRAVEL					Ctat	_												Doto	 (mm/dd/yyyy)	
HISTORY					Stat	е			De	part	ure Date (mm/ac	1/9999)			ĸ	eturn	Date	(mm/aa/yyyy)	
	D	omes	stic						_											
	Des	tinat	tions						_											
									_											
CASE DIS	EASE		Indig	genous	Ir	stat	e. out	of iur	sdiction		Unknov	vn								
IMPORTED	CODI	■		national			state						d, but no	ot al	ole to	dete	rmine	source	state/country	
Imported C	Countr	v		_ Impo	ted St	ate			Impor	ted	County				In	nport	ed C	itv		
Country of																				
County of E											posure									
County of I	.xpusi																			
Outbreak r	elated	d? Y=	yes N =r	no U =unkno	wn		Outb	reak	Name _.				Tra	nsı	miss	ion I	Mode	e		
Comments																				

					L/	ABO	RATO	RY INFORI	MATI	ON								
Test Type	Test Result		Result Units		Test Result uantitative		Da Spec	ate imen ected		pecimen Type		ı	Performir Laborator pecimen	ry		erforming boratory Type		
PERFO	ORMING								IMEN 25	TYPE Saliva		33	Swab		41	Vesicle fluid		
LABORA ⁻	TORY TYPE	1	Bacterial isolate	9			17	NP swab										
1 =C	DC lab	3	Blood Body fluid	10 11			18 19	NP washing Nucleic acid	26 27	Scab Serum		34 35	Swab, skin Swab, nas		42	Viral isolate Other		
2 =comn	nercial lab	4	BAL	12	Dried blood		20	Oral fluid	28	Skin lesion		36	Swab, vesi		44	Unknown		
	pital lab	5	Buccal smear	13			21	Oral swab	29	Specimen	۱ مام میں	37 38	Swab, inte					
	clinical lab lic health	6 7	Buccal swab Capillary blood	14 15			22	Plasma Respiratory	30 31	Lung (BAL)	wasnij	39	Tissue	raD				
	testing lab	8	Cataract	16			24	RNA	32	Stool		40	Urine					
	other		TEST RESULT		255370002=Unsat		ry			ant rise in IgG				56=SARS-CoV		` ,		
9 =un 10828004 =P	ıknown	_	nding =Other (specify)		385660001 =Not do PHC126= Vaccine t		ain	PHC402=Sig		rise in IgG : SARS CoV-2 E	31.1 7 (5	01Y V1\				51 (501Y.V2) 501Y.V3) Gamma		
260385009=			=Unknown		PHC127=Wild type	··				SARS COV-2 E	<u> </u>			95 =SARS-CoV				
280414007=	equivocal	823	34004=Indeterminate	:	PHC2325=Other va	ariant (specify)	467971000	124106=	SARS CoV-2 F	P.1 (501\	/.V3)	PLR534	16 =SARS-CoV	/-2 B.1.1.	529 (Omicron)		
					VACCIN	IATIO	оп ні	STORY INI	ORIV	ATION								
Vaccina	ted (has th	е са	se patient ev	er r	eceived a va	ccin	e aga	inst this d	iseas	e)? Y= _V	/es	N=	no	U =unkr	าดพท			
															101111			
	Number of doses against this disease received prior to illness onset? 0-6 (doses) 99=unknown Date of last vaccine dose against this disease prior to illness onset? (mm/dd/yyyy)																	
					•								(mm/dd/yy	ууу)				
was the	case patie	ent v	accinated as	rec	ommenaea	by tr	ne AC	IP? Y=ye	s N	=no U =	unkn	own						
Vaccine	Vaccinat	tion I	Date _{Vaccir}	e	Vaccine	Na	tional	Vaccir	пе Ехр	iration	Va	ccinat	ion V	accine E	vent	Vaccine		
Type	month day	Manuf Lot No. Drug Code				e	Date Record h day year Identifier				Informat	_	Dose					
	month day		year					month	day	year	Id	entifi	er	Source	е	Number		
				.														
				_									 					
206 =Vaccir	nia smallnov r	monke	Vaccine						Va	ccine Eve	nt Inf	ormat	ion Code	 		ccine		
			Vaccine eypox, live attenu mRNA, LNP-S, PF	ated	, PF								ion Code			 ccine lfacturer		
207 =SARS- 208 =SARS-	COV-2 (COVID)-19),)-19),	eypox, live attenu mRNA, LNP-S, PF mRNA, LNP-S, PF	ated 100 30 r	, PF mcg/0.5 mL dos ncg/0.3 mL dose	2			00 =N	lew immuniz	zation r	ecord			Manu	ıfacturer		
207=SARS- 208=SARS- 210=SARS-	COV-2 (COVID COV-2 (COVID COV-2 (COVID)-19),)-19),)-19),	eypox, live attenu mRNA, LNP-S, PF mRNA, LNP-S, PF vector-nr, rS-ChA	ated 100 30 r dOx:	, PF mcg/0.5 mL dos ncg/0.3 mL dose I, PF, 0.5 mL dos	e se	.5ml de		00=N 01=U	lew immuniz	zation r source (ecord historic		- A:	Manu SZ =Astr	afacturer		
207=SARS- 208=SARS- 210=SARS- 211=SARS-	COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID)-19),)-19),)-19),)-19),	eypox, live attenu mRNA, LNP-S, PF mRNA, LNP-S, PF	ated 100 30 r dOxí	, PF mcg/0.5 mL dos ncg/0.3 mL dos L, PF, 0.5 mL dos x-M1 Adjuvant,	e se	.5mL do	ose	00=N 01=U 02=C	lew immuniz Inspecified s Other provide	zation r source (er (histo	ecord historic orical)		- A: - Bi	Manu SZ =Astr	rifacturer Ta Zeneca Tian Nordic		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 213=SARS-	COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID)-19),)-19),)-19),)-19), -19),	eypox, live attenu mRNA, LNP-S, PF mRNA, LNP-S, PF vector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED	ated 100 30 r dOx: Matr 6, PF	, PF mcg/0.5 mL dos ncg/0.3 mL dos L, PF, 0.5 mL dos ix-M1 Adjuvant, , 0.5 mL dose	e se PF, 0.			00=N 01=U 02=C 05=C	lew immuniz Inspecified s Other provide Other registry	zation r source (er (histo y (histo	ecord historic orical) rical)		- A: - BI - JS	Manu SZ=Astr N=Bava SN=Jans	rifacturer ra Zeneca rian Nordic		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS (213=SARS- 225=SARS-	COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID	0-19), 0-19), 0-19), 0-19), 0-19), 0-19),	eypox, live attenu mRNA, LNP-S, PF mRNA, LNP-S, PF vector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM,	ated 100 30 r dOx: Matr 5, PF	, PF mcg/0.5 mL dos ncg/0.3 mL dos L, PF, 0.5 mL dos ix-M1 Adjuvant, , 0.5 mL dose	e Se PF, 0. mcg/0	.5mL d	ose	00=N 01=U 02=C 05=C 06=B	Jew immuniz Inspecified s Other provide Other registry Sirth certifica	zation r source (er (histo y (histo ate (hist	record historic orical) rical)		- A: - Bi - JS - M	Manu SZ=Astr N=Bava SN=Jans IDO=M	a Zeneca rian Nordic		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 213=SARS- 225=SARS- 226=SARS-	COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID	0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19),	eypox, live attenu mRNA, LNP-S, PF mRNA, LNP-S, PF vector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED	ated 100 30 r dOx: Matr 5, PF	, PF mcg/0.5 mL dosencg/0.3 mL dosencg/0.5 mL dosency , PF, 0.5 mL dosency , 0.5 mL dosency , 0.5 mL dosency , adjuvant, PF,5rency	e Se PF, 0. mcg/0 Omcg/	.5mL d 0.5mL	ose dose	00=N 01=U 02=C 05=C 06=B 07=S	lew immuniz Inspecified s Other provide Other registry irth certifica chool record	zation r source (er (histo y (histo ate (histo	record historic orical) rical) corical)		- A: - Bi - JS - M	Manu SZ=Astr N=Bava SN=Jans IDO=M	a Zeneca rian Nordic sen edicago oderna		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 213=SARS- 225=SARS- 226=SARS- 228=SARS- 229=SARS-	COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID COV-2 (COVID	0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19),	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF wector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, a D614, preSdTM, a mRNA, spike prof mRNA, spike prof	ated 100 30 r dOx: Matr 5, PF ASO3 ein, ein,	, PF mcg/0.5 mL dosencg/0.3 mL dosel, PF, 0.5 mL doselx-M1 Adjuvant, 0.5 mL doseladjuvant, PF,5reladjuvant, PF,10 LNP, PF, pediatr LNP, PF, booster	ese PF, 0. mcg/0 mcg/ ic,25n r,50m	0.5mL d 0.5mL o ncg/0.2 cg/0.5r	ose dose 25mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P	Jew immuniz Inspecified s Other provide Other registry Sirth certifica	zation r source (er (histo y (histo ate (histo y (histor	record historic orical) rical) corical) rical)	al)	- A: - BI - JS - M - M	Manu SZ=Astr N=Bava SN=Jans IDO=M	a Zeneca rian Nordic sen edicago oderna vavax		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 213=SARS- 225=SARS- 226=SARS- 228=SARS- 229=SARS- 300=SARS-	COV-2 (COVID	0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19),	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF wector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, a mRNA, spike prof mRNA, spike prof mRNA, spike prof	ated 100 30 r dOx: Matr 6, PF ASO3 ein, ein, ein,	, PF mcg/0.5 mL dose ncg/0.3 mL dose L, PF, 0.5 mL dose ix-M1 Adjuvant, , 0.5 mL dose adjuvant, PF,5r adjuvant, PF,10 LNP, PF, pediatr LNP, PF, boostel LNP, PF, boostel	e se PF, 0. mcg/0 mcg/ ic,25n r,50m r,30m	.5mL d '0.5mL o ncg/0.2 cg/0.5r cg/0.3r	ose dose 25mL dose mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P PHC1	lew immuniz Inspecified s Other provide Other registro irth certifica chool record ublic agency	zation r source (er (histo y (histo d (histo r (histon	record historic orical) rical) corical) rical) rical)	al) I (historical)	- A: - Bi - JS - M - M - N	Manu SZ=Astr N=Bava SN=Jans IDO=M IOD=M VX=No FR=Pfiz	a Zeneca rian Nordic sen edicago oderna vavax		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 213=SARS- 225=SARS- 226=SARS- 228=SARS- 300=SARS- 301=SARS-	COV-2 (COVID	0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19),	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF wector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, a D614, preSdTM, a mRNA, spike prof mRNA, spike prof	ated 100 30 r dOx: Matr 5, PF ASO3 ein, ein, ein,	, PF mcg/0.5 mL dosencg/0.3 mL dosel, PF, 0.5 mL doselx-M1 Adjuvant, 0.5 mL doselx-dijuvant, PF,5reladjuvant, PF,10 LNP, PF, boostelLNP, PF, boostel	mcg/0 mcg/0 mcg/ mcg/ ic,25n r,50m r,30m r,10m	.5mL d '0.5mL o ncg/0.2 cg/0.5r cg/0.3r	ose dose 25mL dose mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P PHC1	lew immuniz Inspecified s Other provide Other registry irth certifica chool record ublic agency	zation r source (er (histo y (histo ate (histo d (histo ot/pare at/pare	record historic prical) rical) rical) rical) rical) rical) ht recall	al) (historical) en record	- A: - Bi - JS - M - M - N' - Pi - Pi	Manu SZ=Astr N=Bava SN=Jans IDO=M IOD=M VX=No FR=Pfiz	a Zeneca rian Nordic sen edicago oderna vavax er		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 213=SARS- 225=SARS- 226=SARS- 228=SARS- 300=SARS- 301=SARS- 510=SARS- 511=SARS-	COV-2 (COVID	0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19),	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF wector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, D614, preSdTM, mRNA, spike proi mRNA, spike proi	ated 100 30 r dOx: Matr 5, PF ASO3 ein, ein, ein, ein, JS (E	, PF mcg/0.5 mL dosencg/0.3 mL dosencg/0.3 mL dosency. The second of the	ese PF, 0.00mcg/00mcg/ic,25n r,50m r,30m r,10m	.5mL d '0.5mL o ncg/0.2 cg/0.5r cg/0.3r	ose dose 25mL dose mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P PHC1	lew immunia Inspecified s Other provide Other registry iirth certifica chool record ublic agency 1435=Patien	zation r source (er (history (history d (history d (history nt/paren nt/paren	record historic orical) rical) rical) rical) rical) rical) nt recali nt writte	al) (historical) en record	- A: - Bi - JS - M - M - N - N - Pi - Pi - Si	Manu SZ=Astri N=Bava SN=Jans IDO=M IOD=M VX=No FR=Pfiz MC=San	a Zeneca rian Nordic sen edicago oderna vavax er		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 213=SARS- 225=SARS- 226=SARS- 229=SARS- 300=SARS- 301=SARS- 510=SARS- 511=SARS-	COV-2 (COVID	1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19), 1-19),	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF wector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, D614, preSdTM, MRNA, spike proi mRNA, spike proi lnactivated Non- ULP, Non-US (Me	ated 100 30 r dOx: Matr 5, PF ASO3 ein, ein, ein, JS (E	, PF mcg/0.5 mL dose ncg/0.3 mL dose L, PF, 0.5 mL dose ix-M1 Adjuvant, , 0.5 mL dose adjuvant, PF,5r adjuvant, PF,10 LNP, PF, pediatr LNP, PF, boostel LNP, PF, boostel LNP, PF, boostel LNP, Sinopharm inovac, Coronal go, Covifenz)	mcg/0 0mcg/0mcg/ ic,25n r,50m r,30m r,10m)	0.5mL d (0.5mL d mcg/0.2 cg/0.5r cg/0.3r cg/0.2r	ose dose 25mL dose mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P PHC1 PHC1	lew immuniz Inspecified s Other provide Other registry irth certifica chool record ublic agency 1435=Patien 1436=Patien	zation r source (er (histo y (histo ate (histo y (histo at/pare at/pare provide	record historical) rical) rical) rical) rical) rical) nt recali nt writte	al) (historical) en record	- A: - Bi - JS - M - M - N - N - Pi - Pi - Si	Manu SZ=Astri N=Bava SN=Jans IDO=M IOD=M VX=No FR=Pfiz MC=San	a Zeneca rian Nordic sen edicago oderna vavax er nofi Pasteur		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 213=SARS- 225=SARS- 226=SARS- 228=SARS- 229=SARS- 300=SARS- 301=SARS- 510=SARS- 511=SARS- 512=SARS- 513=SARS-	COV-2 (COVID	0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19), 0-19),	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF wector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, D614, preSdTM, mRNA, spike proi mRNA, spike proi	ated 100 30 r 30 r 40 4 5, PF 4 4 5 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	, PF mcg/0.5 mL dosencg/0.3 mL dosencg/0.3 mL dosel, PF, 0.5 mL dosels adjuvant, PF,5rels adjuvant, PF,10 LNP, PF, boostel LNP, PF, boostel LNP, PF, boostel LNP, PF, boostel LNP, Coronal (so, Covifenz) ifei Longcom, Zi	mcg/0 0mcg/0mcg/ ic,25n r,50m r,30m r,10m)	0.5mL d (0.5mL d mcg/0.2 cg/0.5r cg/0.3r cg/0.2r	ose dose 25mL dose mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P PHC1 PHC1 PHC1 PP=P	Jew immuniz Inspecified s Other provide Other registry irth certifica chool record ublic agency 1435=Patien 1436=Immunization	zation r source (er (histo y (histo ate (histo y (histo at/pare at/pare provide	record historical) rical) rical) rical) rical) rical) nt recali nt writte	al) (historical) en record	- A: - Bi - JS - M - M - N - N - Pi - Pi - Si	Manu SZ=Astri N=Bava SN=Jans IDO=M IOD=M VX=No FR=Pfiz MC=San	a Zeneca rian Nordic sen edicago oderna vavax er nofi Pasteur		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 225=SARS- 226=SARS- 228=SARS- 229=SARS- 300=SARS- 510=SARS- 511=SARS- 512=SARS- 513=SARS- 514=SARS- 515=SARS-	COV-2 (COVID	1-19), (-	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF mRNA, LNP-S, PF vector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, D614, preSdTM, mRNA, spike proi mRNA, spike proi lnactivated Non- lnactivated Non- lnactivated Non- VLP, Non-US (Me PS, Non-US (Anho DNA, Non-US (Medi	ated 100 30 r dOx Matr 5, PF ASO3 ein, ein, ein, jS (E dicag dicag li, Zh lus C	, PF mcg/0.5 mL dose ncg/0.3 mL dose L, PF, 0.5 mL dose ix-M1 Adjuvant, , 0.5 mL dose adjuvant, PF,5r adjuvant, PF,10 LNP, PF, pediatr LNP, PF, boostel LNP, PF, boostel LNP, PF, boostel LNP, Sinopharm inovac, Coronav go, Covifenz) ifei Longcom, Zi adila, ZyCoV-D) MVC-COV1901)	mcg/0 Dmcg/ ic,25n r,50m r,10m) /acc)	0.5mL d (0.5mL d mcg/0.2 cg/0.5r cg/0.3r cg/0.2r	ose dose 25mL dose mL dose mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P PHC1 PHC1 PHC1 PP=P 1842	lew immunized specified so their provide other registry iirth certification chool record ublic agency 1435=Patien 1436=Patien 1936=Immunication care 125006=Medical provides a constant of the	zation r source (er (histo y (histo ate (histo y (histo at/pare at/pare provide	record historical) rical) rical) rical) rical) rical) nt recali nt writte	al) (historical) en record	- A: - Bi - JS - M - M - N - N - Pi - Pi - Si	Manu SZ=Astri N=Bava SN=Jans IDO=M IOD=M VX=No FR=Pfiz MC=San	a Zeneca rian Nordic sen edicago oderna vavax er nofi Pasteur		
207=SARS- 208=SARS- 210=SARS- 211=SARS- 212=SARS- 225=SARS- 226=SARS- 228=SARS- 300=SARS- 301=SARS- 510=SARS- 511=SARS- 512=SARS- 513=SARS- 514=SARS- 515=SARS- 516=SARS-	COV-2 (COVID	1-19), (-	eypox, live attenumRNA, LNP-S, PF mRNA, LNP-S, PF mRNA, LNP-S, PF vector-nr, rS-ChA rS-nanoparticle+l vector-nr, rS-Ad2 UNSPECIFIED D614, preSdTM, D614, preSdTM, Spike proi mRNA, spike proi mRNA, spike proi mRNA, spike proi mRNA, spike proi mRNA, spike proi lnactivated Non- lnactivated Non- ULP, Non-US (Me PS, Non-US (Anho DNA, Non-US-(Zyo	ated 100 30 r r dOx: Matr 5, PF ASO3 ein, ein, ein, JS (B dicag dicag lus C ggen, JS (N	, PF mcg/0.5 mL dose ncg/0.3 mL dose L, PF, 0.5 mL dose ix-M1 Adjuvant, , 0.5 mL dose adjuvant, PF,5r adjuvant, PF,10 LNP, PF, boostel LNP, PF, boostel LNP, PF, boostel LNP, PF, boostel LNP, Sinopharm inovac, Coronav go, Covifenz) ifei Longcom, Zi adila, ZyCoV-D) MVC-COV1901) dinhai Biotechno	mcg/0 Omcg/ ic,25n r,50m r,10m) /acc)	0.5mL d 0.5mL d ncg/0.2 cg/0.5r cg/0.3r cg/0.2r	ose dose 25mL dose mL dose mL dose mL dose	00=N 01=U 02=C 05=C 06=B 07=S 08=P PHC1 PHC1 PHC1 PP=P 1842	Jew immuniz Inspecified s Other provide Other registry irth certifica chool record ublic agency 1435=Patien 1436=Patien 1936=Immunizimary care 125006=Med	zation r source (er (histo y (histo ate (histo y (histo at/pare at/pare provide	record historical) rical) rical) rical) rical) rical) nt recali nt writte	al) (historical) en record	- A: - Bi - JS - M - M - N - N - Pi - Pi - Si	Manu SZ=Astri N=Bava SN=Jans IDO=M IOD=M VX=No FR=Pfiz MC=San	a Zeneca rian Nordic sen edicago oderna vavax er nofi Pasteur		

Reason Not Vaccina 1=religious exemption 2=medical contraindication 3=philosophical objection 4=lab evidence of previous o	5=MD diagnosis of previous disease 6=too young 7=parent/patient refusal			10=parent 11=vaccine	:/patient fo e record in	orgot to vaccinate complete/unavailab port of previous disc	14=misse le 15=foreig	13=parent/patient unaware of recommendation 14=missed opportunity 15=foreign visitor 16=immigrant 17=vaccine not available					
Vaccine History Com	nments												
					CASE NO	OTIFICA [*]	TION						
CONDITION CODE	11	1065	Imme	ediate Na	tional No	otifiable	e Condition	Y =yes N =r	no U =u	nknown]		
Date of First Verbal I	ition to		month day year Date (of Electronic Case Notification to CDC							
State Case ID	tate Case ID						Date First Ele	ectonic Subm		nonth day year			
Notification Result S	tatus	O Final	l results	O Corr	ection	O Ca	nnot obtain	Jurisdiction	Code				
Binational Reporting	Criteri	a			MMWR	WEEK		MMWR YEA	AR				
Current Occupation	(type of w	ork patien	t does)				Current Occupation Standardized (NIOCCS code)						
Current Industry (type	of busine	ss/industr	y in which pat	tient works)			Current Industry Standardized (NIOCCS code)						
Person Reporting to NAME				·		Person Reporting to CDC Email@							
				CLIN			INITION§						
	Meets supportive laboratory evidence [¶] OR Meets vital records criteria [#] with no confirmatory or presumptive laboratory evidence for SARS-CoV-2												
					Pro	obable							
 Meets presumptive^{††} 	laborat	ory evid	ence.										
					Cor	nfirmed							
 Meets confirmatory[‡] 	[‡] labora	tory evid	dence.										
*A death certificate the contributing to death	V-2 RNA isdiction pect case at lists C	or spec s may o _l es should	ific antigen pt to place d not be inc	using a te them in a l	st perform registry fo	med with or other s.]	epidemiological	analyses or in		·			
^{††} Detection of SARS-Co provider.	oV-2 spe	ecific ant	igen in a cl	inical or po	ost-morte	em speci	men using a diag	gnostic test pe	rformed b	y a CLIA-certified			
**Detection of SARS-Co certified provider, OF Detection of SARS-Co	₹		•				_	•	_ cation test	performed by a	CLIA-		

^{\$} https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/ps2022/22-ID-01_COVID19.pdf